Finance

Lists
Q3 2026 earnings • released • EPS beat +23.33%
See results
ANRO:NYSE
Alto Neuroscience Inc
$29.54
-3.50%
(-1.07) 1D
$29.54
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:03 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANRO...
Open
$30.01
High
$30.76
Low
$28.54
Mkt. cap
1.18B
Avg. vol.
643.76K
Volume
610.93K
52-wk high
$37.48
52-wk low
$10.80
EPS
-$2.46
Shares outstanding
40.11M
No. of employees
68
Open
$30.01
High
$30.76
Low
$28.54
Mkt. cap
1.18B
Avg. vol.
643.76K
Volume
610.93K
52-wk high
$37.48
52-wk low
$10.80
EPS
-$2.46
Shares outstanding
40.11M
No. of employees
68
News stories
From web sources and news partners
About Alto Neuroscience Inc
CEO-
Employees68
Founded2019
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 5 analysts giving stock ratings to ANRO in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ANRO in the last 3 months.
Highest
Current $29.54
$60.00 (+103.11%)
Average
$47.00 (+59.11%)
Lowest
$37.00 (+25.25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Justin Walsh
JonesTrading
Buy
Reiterated
$44.00
+49%
11/12/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$60.00
+103.1%
11/12/2026
Thomas Shrader
BTIG
Buy
Maintained
$37.00
+25.3%
11/11/2026
Ritu Baral
TD Cowen
Buy
Maintained
-
-
11/11/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
10/02/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
08/14/2026
Andrew Tsai
Jefferies
Buy
Maintained
$40.00
+35.4%
08/13/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$36.00
+21.9%
05/18/2026
Laura Chico
Wedbush
Hold
Maintained
$24.00
-18.8%
05/14/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$30.00
+1.6%
04/21/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$33.00
+11.7%
04/02/2026
Last report
Nov 10, 2026
Fiscal period
Q3 2026
-$0.54 / -$0.70
+23.33%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12.00M
20.29M
22.11M
18.16M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.06M
6.84M
7.02M
9.06M
Operating expense
17.06M
27.14M
29.13M
27.22M
Total operating expenses
17.06M
27.14M
29.13M
27.22M
Operating income
-17.06M
-27.14M
-29.13M
-27.22M
Other non operating income
-113.00K
-115.00K
-130.00K
-36.00K
EBT including unusual items
-16.18M
-26.24M
-27.64M
-25.12M
EBT excluding unusual items
-16.18M
-26.24M
-27.64M
-25.12M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16.18M
-26.24M
-27.64M
-25.12M
Net profit margin
-
-
-
-
Earnings per share
-0.45
-0.80
-0.65
-0.54
Interest and investment income
1.56M
1.56M
2.11M
2.60M
Interest expense
-575.00K
-545.00K
-491.00K
-463.00K
Net interest expenses
986.00K
1.02M
1.62M
2.14M
Depreciation and amortization charges
-
-
-
-
EBITDA
-16.90M
-26.95M
-28.94M
-27.04M
Gain or loss from assets sale
-
9.00K
-
8.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps